BETA-TT8 / Filamon - LARVOL DELTA

Australia-based Filamon Limited has registered a Phase Ib/IIa first-in-human clinical trial of BETA-TT8 Ophthalmic Gel 3.8%, a topical small-molecule MEK/ERK (mitogen-activated protein kinase) pathway inhibitor, in patients with neovascular age-related macular degeneration (wetAMD). (AllSci Corp) - "The study, listed on ClinicalTrials.gov as NCT07766473 with a status of 'not yet recruiting,' is expected to open at four Australian sites in Q3 2026, with primary completion targeted for Q1 2027....The open-label, randomized study will enroll 24 patients with stable wetAMD who have previously received at least three intravitreal aflibercept (Eylea) injections."

Trial primary completion date • Trial status • Wet Age-related Macular Degeneration

BEyOND: First in Human Study of BETA-TT8 in wetAge-related Macular Degeneration (wetAMD) (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: Filamon LTD

First-in-human • New P1/2 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration